Health
Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases
SAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. wholly-owned subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. (Stock Cod e: 2563.HK), today announced that the first patient has been dosed for one of its key oversea clinical studies: the U.S. pivotal clinical stud...
2025-12-16 12:55
Enginprime Medical Inc Announces First-in-Human Study of Its Leading OpusOne™ pVAD
HANGZHOU, China, Dec. 15, 2025 /PRNewswire/ -- Enginprime Medical Inc ("Enginprime"), an emerging leader in percutaneous ventricular assist device (pVAD) technologies and a Voyagers Capital portfolio company, today announced that its industry leading pVAD, OpusOne™, has entered its first-in-human...
2025-12-16 06:00
824
HitGen Submits Commitment Letter to Science Based Targets initiative (SBTi)
CHENGDU, China, Dec. 15, 2025 /PRNewswire/ -- HitGen Inc. (hereinafter referred to as "HitGen", SSE: 688222.SH), announced it has officially submitted its commitment letter to the Science Based Targets initiative (SBTi). HitGen has pledged to set near-term science-based targets within the next tw...
2025-12-15 22:30
755
Neurabody Enters the UK Market with Selfridges Launch, Showcasing the Future of AI-Driven Ergonomics
LONDON, Dec. 15, 2025 /PRNewswire/ -- Neurabody, the AI-driven posture science
company transforming modern ergonomics, today announced its official launch at
Selfridges London, marking a significant milestone in the company's global
expansion and consumer entry into the UK market.
2025-12-15 22:00
681
Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Translational Oncology Research
Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo oncology research and development programs SEOUL, South Korea, Dec. 15, 2025 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precisi...
2025-12-15 22:00
967
Leadgene Biosolutions, Inc., (Formerly CYTENA BPS), Announces Corporate Rebranding to Mark a New Phase of Growth within the Leadgene Group
TAIPEI, Dec. 15, 2025 /PRNewswire/ -- Leadgene Biosolutions, Inc. (formerly CYTENA BPS), following its transition out of the BICO Group, now officially integrates with Leadgene Biomedical, a biotechnology company specializing in recombinant proteins, antibodies, and diagnostic reagent development...
2025-12-15 21:00
705
Minghui Pharmaceutical Announces FDA clearance of IND to Initiate Global Phase Ⅲ Trials of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody, in Thyroid Eye Disease
SHANGHAI and HANGZHOU, China, Dec. 15, 2025 /PRNewswire/ -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New D...
2025-12-15 18:00
2978
Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.
STOCKHOLM, Dec. 15, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings. Under the terms of the agreement, Sobi will pay up ...
2025-12-15 14:06
1119
Keeping Loved Ones Active and Healthy During the Holidays with VARON Oxygen Concentrators
NEW YORK, Dec. 12, 2025 /PRNewswire/ -- The holiday season
2025-12-12 23:16
2289
/DISREGARD RELEASE: Ractigen Therapeutics/
We are advised by Ractigen Therapeutics that journalists and other readers should disregard the news release, Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18 for Duchenne Muscular Dystrophy, issued7:30AM 12-Dec-2025 over PR Newswire, as the release contained erroneous information...
2025-12-12 23:10
2520
United Imaging Intelligence at RSNA 2025: Reshaping Medicine with AI Agents
SHANGHAI, Dec. 12, 2025 /PRNewswire/ -- Under the theme "Imaging the Individual", RSNA 2025 challenged the radiology community to push into new frontiers and close the gap between personalized care and global health disparities. This year,United Imaging Intelligence (UII), the AI-focused subsidi...
2025-12-12 22:00
2675
Strategic Partnership | Sanyou Bio and KanryBio Forge Partnership to Co-Develop Key Reagents and Products for Biomarker Assay Kits
SHANGHAI, Dec. 12, 2025 /PRNewswire/ -- On December 10, 2025, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Bio") and Wenzhou KanryBio Biotech Co., Ltd. ("KanryBio")announced a strategic collaboration agreement. The partnership will focus on the joint development of key reagents and p...
2025-12-12 22:00
3058
Global Attention: POGMENT Biomimetic Collagen "Stable Triple-Helix Breakthrough" --Unconventional and Astonishing
— LivingPhoenix Forum's 12 Conference Presentation Ignite International and Domestic Academia, Hailed by Academicians as the "iPhone Moment for Extracellular Matrix Research" CHENGDU, China, Dec. 12, 2025 /PRNewswire/ -- LivingPhoenix Regenerative Technologies has drawn widespread international ...
2025-12-12 21:46
3331
Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18, a Potential Game-Changing saRNA Therapeutic for Duchenne Muscular Dystrophy
NANTONG, China, Dec. 12, 2025 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in its investigator-initiated trial (IIT) of RAG-18 at Peking Union Medical College Hospital (PUMCH...
2025-12-12 21:35
2563
Insilico Medicine and TaiGen Achieves License Agreement to Develop and Commercialize AI-driven PHD Inhibitor for Anemia of Chronic Kidney Disease (CKD)
* Insilico Medicine has licensed TaiGen Biotechnology exclusive rights in the Greater China area to develop, commercialize, and sub-license ISM4808, an AI-driven potential best-in-class oral PHD inhibitor with IND clearance granted in 2023. * The partnership combines Insilico's generative AI ...
2025-12-12 20:00
2101
Smartee Strengthens Clinical Engagement in the DACH Region with First GS Summit in Cologne and Presence at TPAO Congress
COLOGNE, Germany, Dec. 12, 2025 /PRNewswire/ -- Smartee Denti-Technology hosted its first GS-focused clinical summit inCologne on November 27, deepening its collaboration with orthodontists across the DACH region. Although Smartee has operated inGermany for more than 2 years through its local sub...
2025-12-12 17:26
1259
Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab
HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody. The study wi...
2025-12-12 10:31
2360
Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity
* After 12 weeks of treatment, the 4 mg and 6 mg mazdutide groups achieved reductions in BMI from baseline of 8.78% and 10.99%, respectively, with corresponding body weight reductions of 7.72 kg and 8.65 kg. These results were significantly superior to those observed in the placebo group (BMI r...
2025-12-12 08:00
2043
FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial
Highlights: * FDA has completed their review of the Neurizon NUZ-001 regimen to the HEALEY ALS Platform Trial Master Protocol * This marks the official entry of NUZ-001 as Regimen I in the HEALEY ALS Platform Trial * Next steps include obtaining single IRB approval, site initiations and cl...
2025-12-12 04:49
1716
Datasea Announces Breakthrough in Acoustic-Driven Brain-Computer Interface Technology
Developing Healthcare and Intelligent Interaction Through Core Acoustic Innovation BEIJING, Dec. 11, 2025 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a global technology enterprise specializing in acoustic high-tech innovations and AI multimodal digital solutions, t...
2025-12-11 22:30
1333
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
Tiiny AI Reveals World's Smallest Personal AI Supercomputer, Verified by Guinness World Records
[Picked up by 285 media titles]
2025-12-10 16:00
Asia Pacific Defies Global Headwinds: Mastercard Economics Institute 2026 Outlook
[Picked up by 277 media titles]
2025-12-10 09:00